Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab

Effect of hypoxia-inducible factor-1 alpha expression on survival in patients with metastatic cervical squamous cell carcinoma treated with first-line chemotherapy and bevacizumab

This study addresses the gap in understanding the prognostic relevance of hypoxia-inducible factor-1 alpha (HIF-1 alpha) expression in metastatic cervical squamous cell carcinoma (SCC) patients undergoing anti-vascular endothelial growth factor-based therapy. A retrospective multicenter study (n =...

Full description

Bibliographic Details
Main Authors:	Hasan Cagri Yildirim, Hicran Anik, Deniz Ates Ozdemir, Rashad Ismayilov, Arif Akyildiz, Kerim Cayiroz, Fahri Ceyhan, Oguzalp Kavruk, Deniz Can Guven, Ozturk Ates, Alp Usubutun, Zafer Arik
Format:	Article
Language:	English
Published:	Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina 2024-03-01
Series:	Biomolecules & Biomedicine
Subjects:	Metastatic cervical cancer squamous cell carcinoma (SCC) vascular endothelial growth factor (VEGF) hypoxia-inducible factor-1 alpha (HIF-1 alpha) bevacizumab
Online Access:	https://www.bjbms.org/ojs/index.php/bjbms/article/view/10255

Similar Items

Paths for Improving Bevacizumab Available in 2018: The ADZT Regimen for Better Glioblastoma Treatment
by: Richard E. Kast
Published: (2018-09-01)

Evaluating the causes of retinopathy of prematurity relapse following intravitreal bevacizumab injection
by: Amir Eftekhari Milani, et al.
Published: (2024-06-01)

Resolution of Refractory Corneal Neovascularization with Subconjunctival Bevacizumab
by: Anna Krystyna Britton, et al.
Published: (2020-12-01)

The outcome of Concurrent Diode Laser Cyclophotocoagulation and Bevacizumab for Treatment of Neovascular Glaucoma
by: Riad Elzaher Hassan Ahmed, et al.
Published: (2022-03-01)

INTEGRATION OF BEVACIZUMAB IN METASTATIC COLORECTAL CANCER CHEMOTHERAPY REGIMENS IN 2 CLINICAL CENTERS IN MOSCOW AND SAINT PETERSBURG
by: N. V. Dobrova, et al.
Published: (2015-02-01)

Diffusing alpha-emitters radiation therapy in combination with temozolomide or bevacizumab in human glioblastoma multiforme xenografts
by: Yossi Nishri, et al.
Published: (2022-09-01)

Update on Chemotherapeutic Approaches and Management of Bevacizumab Usage for Glioblastoma
by: Yusuke Funakoshi, et al.
Published: (2020-12-01)

Effects of tumor necrosis factor-alpha inhibitors on lipid profiles in patients with psoriasis: a systematic review and meta-analysis
by: Liang Su, et al.
Published: (2024-03-01)

Necrotizing Fasciitis as Complication of Combined Use of Bevacizumab with Chemotherapy
by: Cantürk Emir, et al.
Published: (2023-03-01)

Reversal of cerebral radiation necrosis with bevacizumab treatment in 17 Chinese patients
by: Wang Yang, et al.
Published: (2012-08-01)

Clinical risk factors of bevacizumab-related hypertension in patients with metastatic colorectal cancer: a retrospective study
by: Zhuoling Zheng, et al.
Published: (2024-10-01)

The role of visfatin levels in gingival crevicular fluid as a potential biomarker in the relationship between obesity and periodontal disease
by: Deniz ÇETİNER, et al.

Non-Surgical Management of Recurrent Naso-Orbital Hemangiomas with Bevacizumab: A Case Report
by: Liu S, et al.
Published: (2024-10-01)

Bevacizumab suppressed degenerative changes in articular cartilage explants from patients with osteoarthritis of the knee
by: Masaichi Sotozawa, et al.
Published: (2023-01-01)

Comparative Analysis of Alpha and Beta HPV E6 Oncoproteins: Insights into Functional Distinctions and Divergent Mechanisms of Pathogenesis
by: Josipa Skelin, et al.
Published: (2023-11-01)

Effects of anti-vascular endothelial growth factor monoclonal antibody (bevacizumab) on lens epithelial cells
by: Jun JH, et al.
Published: (2016-06-01)

Mutations in transcription factor as rare causes of diabetes in pregnancy
by: Natalia A. Zubkova, et al.
Published: (2019-08-01)

Transforming Growth Factor-alpha Induce Synthesis of alpha-1-Antitryspin in Human Hepatoma Cell Line (HepG2)
by: Mohammad Taghi Goodarzi
Published: (1999-03-01)

Functional characterization of rs2229094 (T>C) polymorphism in the tumor necrosis factor locus and lymphotoxin alpha expression in human retina: the Retina 4 project
by: Pastor-Idoate S, et al.
Published: (2017-05-01)

The real-world efficacy and toxicity of first-line paclitaxel and cisplatin with bevacizumab in platinum-naïve primary stage IVB cervical cancer
by: Junhwan Kim, et al.
Published: (2025-01-01)

Endophthalmitis Postintravitreal Bevacizumab Injections: Incidence, Management, and Visual Outcome in Tertiary Care Center in Pakistan
by: Amna Rizwan, et al.
Published: (2022-01-01)

Suppression of Neovascularization by Topical and Subconjunctival Bevacizumab After High-Risk Corneal Transplantation
by: Thomas H. Dohlman, MD, et al.
Published: (2024-07-01)

Intravitreal bevacizumab (Avastin) treatment of diffuse diabetic macular edema in an Indian population
by: Kumar Atul, et al.
Published: (2007-01-01)

Intravitreal bevacizumab plus macular laser photocoagulation for treatment of diabetic macular edema
by: Ahmed H Mohamed
Published: (2016-01-01)

Direct antitumor activity of bevacizumab: an overlooked mechanism?
by: Zhiyong Wang, et al.
Published: (2024-04-01)

The Effect of Aerobic Training on Tumor Necrosis Factor alpha, Hypoxia-Inducible Factor-1 alpha & Vascular Endothelial Growth Factor Gene Expression in Cardiac Tissue of Diabetic Rats
by: Fariba Bakhtiari, et al.
Published: (2020-06-01)

Subconjunctival Bevacizumab Injection in Treatment of Pterygium
by: Mohammad Reza Besharati, et al.
Published: (2011-03-01)

Changes in vitreous VEGF, bFGF and fibrosis in proliferative diabetic retinopathy after intravitreal bevacizumab
by: Jiu-Ke Li, et al.
Published: (2015-12-01)

The assessment of TNF-α interaction with oligopeptide Trp-Asn-Trp-Val in vitro
by: T.V. Ryabtseva, et al.
Published: (2022-08-01)

Visibility, wind speed, and dew point temperature are important factors in SARS‐CoV‐2 transmissibility
by: Dansha Zhou, et al.
Published: (2022-04-01)

Incidence of Toxoplasmosis in Psoriasis Patients and Possible Correlation with Tumor Necrosis Factor-α
by: Entsar J. Saheb, et al.
Published: (2020-03-01)

Histone deacetylase inhibitor givinostat has ameliorative effect in the colitis model
by: Cengiz Dibekoğlu, et al.
Published: (2022-07-01)

PERSPECTIVES ON USE OF BEVACIZUMAB IN PATIENTS WITH NEUROENDOCRINE TUMORS. CASE REPORT
by: G. S. Emelianova, et al.
Published: (2017-12-01)

Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell  Lung Cancer Patients with Acquired EGFR T790M Mutation
by: Yanfei GU, et al.
Published: (2022-12-01)

Bevacizumab (Avegra®) for the treatment of gynecological cancers: joint experience of several centers
by: A. G. Kedrova, et al.
Published: (2021-03-01)

The Effectiveness of Bevacizumab in COVID-19 Pneumonia Among Critically Ill Patients
by: Karthikkeyan Rajachandran, et al.
Published: (2022-09-01)

Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
by: Masatoshi Kudo, et al.
Published: (2023-11-01)

Bevacizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Mongolian Patients with Diabetic Macular Edema
by: Anaraa Toishubai, et al.
Published: (2016-06-01)

The Correlation between Predictive Factors and Intravitreal Bevacizumab Therapy Outcomes in Central Retinal Vein Occlusion
by: SA Rasoulinejad, et al.
Published: (2022-03-01)

Enhancement of radiation response with bevacizumab
by: Hoang Tien, et al.
Published: (2012-04-01)